Drugs Made In America Acquisition (DMAAR) Cash from Operations (2025)

Drugs Made In America Acquisition (DMAAR) posted Cash from Operations of 125180.0 for Q4 2025, down 123.11% on a QoQ basis from 56108.0 in Q3 2025.

Drugs Made In America Acquisition (DMAAR) Cash from Operations (2025) Analysis & Trends

Drugs Made In America Acquisition's Cash from Operations history runs 1 years deep, the most recent figure standing at 125180.0 for Q4 2025.

Quarterly Cash from Operations changed N/A year-over-year to 125180.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 539187.0 (changed N/A YoY) and the FY2025 annual result came in at 539187.0, down 213.0% from the prior year.
Cash from Operations was 125180.0 for Q4 2025 at Drugs Made In America Acquisition, down from 56108.0 in the prior quarter.
Across five years, Cash from Operations topped out at 56108.0 in Q3 2025 and bottomed at 251244.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Operations (Qtr)
1	SIM Acquisition Corp. I	314.52 Mn	314.52 Mn	-	-299,290.00
2	Thayer Ventures Acquisition	208.29 Mn	208.29 Mn	-	-260,081.00
3	Newbury Street II Acquisition	185.26 Mn	185.26 Mn	-	-275,113.00
4	Dynamix	178.78 Mn	178.78 Mn	-	-427,207.00
5	Hallmark Venture	103.01 Mn	102.76 Mn	-	-59,077.00
6	Voyager Acquisition	99.58 Mn	99.45 Mn	-	-
7	Gores Holdings X	95.80 Mn	95.37 Mn	-	-267,322.00
8	Archimedes Tech SPAC Partners	89.88 Mn	89.88 Mn	-	-45,072.00
9	Cohen Circle Acquisition	80.05 Mn	80.05 Mn	-	-396,098.00
10	Drugs Made In America Acquisition	1.46 Mn	1.46 Mn	-	-125,180.00

Download Data